Fortnightly review. Modern drug treatment of chronic asthma

British Medical Journal

Volumn 318, Issue 7180, 1999, Pages 380-384

  Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST;

ASTHMA; DRUG EFFICACY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MEDICAL LITERATURE; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 0033528240     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7180.380     Document Type: Review

References (37)

1. 1 British guidelines on asthma mangement: 1995 review and position statement. Thorax 1997;52(suppl 1):S1-21.
2. 2 National Asthma Education and Prevention Programme Expert Panel. National Asthma Education and Prevention Programme Expert Panel report II. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997. (Publication 97 4051.)
3. 3 Lipworth BJ.Treatment of acute asthma. Lancet 1997;350(suppl II): 18-23.
4. 4 Barnes PJ, Pedersen S, Busse WW Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157(suppl):S1-53.
5. 2-agonist terbutaline on airway inflammation in newly diagnosed asthma. J Allergy Clin Immunol 1992;90:32-42.
6. 6 Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997;52:55-8.
7. 7 Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996;9:1427-32.
8. 8 Donnelly R, Williams KM, Baker B, Badcock CA, Day RO, Scale PJ. Effects of budesonide and fluticasone on 24 hour plasma cortisol: a dose response study. Am J Respir Crit Care Med 1997;156:1746-51.
9. 9 Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: benefits and risks. In: Chapman K, ed. Semin Respir Crit Care Med 1998;19:633-54.
10. 10 Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-76.
11. 11 Silverstein MD, Yunginger JW, Reed CE, Patterson T, Zimmerman D, Li JTC, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997;99:166-74.
12. 12 McCowan C, Neville RG, Thomas GE, Crombie IK, Clark RA, Ricketts IW, et al. Effect of asthma and its treatment in growth: four year follow-up of cohort of children from general practices in Tayside, Scotland. BMJ 1998;316:668-72.
13. 13 Toogood JH, Baskerville JC, Markov AE, Hodesman AB, Frarher LG, Jennings B, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
14. 14 Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE. Crossectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 1997;52:853-60.
15. 15 Cumming RG, Leeder SR, Mitchell P. Use of inhaled corticosteroids and the risks of cataracts. N Engl J Med 1997;3:3378-4014.
16. 16 Garbe E, Le Lorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open angle glaucoma. JAMA 1997;277:722-7.
17. 17 Roy A, LeBlanc C, Paquete L, Ghazzo M, Cole J, Cartier A, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency in association with adrenal function. Eur Respir J 1996;9:226-34.
18. 18 Manolitsas ND, Wang G, Devalia JL, Trigg CJ, McAulay AE, Davies RJ, et al. Regular albuterol, nedocromil sodium and bronchial inflammation in asthma. Am J Respir Crit Care Med 1995;152:1925-30.
19. 19 Sampson A, Holgate S. Leukotriene modifiers in the treatment of asthma. BMJ 1998;16:1257-8.
20. 20 Virchow JC, Hassal SM, Summerton L, Harris A. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high dose inhaled corticosteroids [abstract]. J Invest Med 1997;45:286A.
21. 21 Leff JA, Israel E, Noonan MJ. Finn AF, Godard P, Lufdahl CG, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability [abstract]. Am J Respir Crit Care Med 1997;155(suppl):976.
22. 22 Nayak AS, Anderson P, Charous BL, Williams F, Simonson K. Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low dose inhaled corticosteroids. J Allergy Clin Immunol 1998;101(supl):S233.
23. 23 Merck Sharp & Dohme. Data on File. In: Singulair product sheet. Hoddesdon:MSD, 1998.
24. 24 Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss T, et al. Montelukast for chronic asthma in 6-14 year old children. JAMA 1998;279:1181-6.
25. 25 Reiss TF, Chervinsky P, Dockhorn KJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomised, double-blind trial. Arch Intern Med 1998;158:1213-20.
26. 26 Turpin JA, Edelman JM, DeLucca PT, Pearlman DS. Chronic administration of montelukast (MK-0476) is superior to inhaled salmeterol in the prevention of exercise induced bronchoconstriction (EIB) [abstract]. Am J Respir Crit Care Med 1998;157(suppl):A456.
27. 27 Malmstrom K, Meltzer E, Prenner B, Lu S, Weinstein S, Wolfe J, et al. Effects of montelukast (a leukotriene receptor antagonist), loratidine, montelukast and loratidine and placebo in seasonal allergic rhinitis and conjunctivitis. J Allergy Clin Immunol 1998;101(suppl):S97.
28. 28 Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukase on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998;53:835-41.
29. 29 Reicin AS, Wenstein SF, White R, Fineman SM, Nguyen H, Geissler L, et al. Montelukast and loratidine compared to montelukast alone produces additional benefit in the treatment of chronic asthma [abstract]. Am J Respir Crit Care Med 1998;157(suppl):A416.
30. 30 Kidney J, Diminguez M, Taylor PM, Rose M, Chung KF, Barnes PJ, et al. Immunomodulation by theophylline in asthma, demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995;151:1907-14.
31. 31 Evans DJ, Taylor DA, Zetterstrom U, Fan Chung K, O'Connor BJ, Barnes PJ. A comparison of low dose inhaled budesonide plus theophylline and high dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
32. 32 Sears MR, Taylor DR, Print CG, Lake DG, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
33. 33 Pauwels R, Lofdahl CG, Postma D, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
34. 34 McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effect of salmeterol in airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30.
35. 35 Ramage L, Lipworth BJ, Ingham CG, Cree TA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
36. 36 Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998;104:431-8.
37. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation on moderately severe stable asthmatics. Lancet 1997;350:995-9.